"10.1371_journal.pone.0035196","plos one","2012-04-09T00:00:00Z","Rory Blackler; Stephanie Syer; Manlio Bolla; Ennio Ongini; John L Wallace","Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada; NicOx Research Institute, Milan, Italy","Conceived and designed the experiments: RB SS EO MB JLW. Performed the experiments: RB SS. Analyzed the data: RB SS EO MB JLW. Wrote the paper: RB EO MB JLW.","The authors have the following competing interests: Dr. Bolla and Dr. Ongini are employed by NicOx S.A. Dr. Wallace holds shares in Antibe Therapteutis. ATB-346 (2-(6-methoxy-napthalen-2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester) was provided and is manufactured by Antibe Therapeutics Inc. (Toronto, ON, Canada). NCX 429 [(S)-6-(nitrooxy)hexyl 2-(6-methoxynaphthalen-2-yl)propanoate] was provided and is manufactured by NicOx S.A. There are no other patents, products in development or other marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","04","Rory Blackler","RB",5,TRUE,5,2,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
